Format

Send to

Choose Destination
Biochem Soc Trans. 2014 Aug;42(4):752-7. doi: 10.1042/BST20140035.

Resistance acquisition to MDM2 inhibitors.

Author information

1
*Institut für Medizinische Virologie, Klinikum der Goethe-Universität, Paul-Ehrlich-Straße 40, 60596 Frankfurt am Main, Germany.
2
§School of Chemistry, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.
3
∥Centre for Molecular Processing and School of Biosciences, University of Kent, Canterbury CT5 3RL, U.K.

Abstract

Various experimental strategies aim to (re)activate p53 signalling in cancer cells. The most advanced clinically are small-molecule inhibitors of the autoregulatory interaction between p53 and MDM2 (murine double minute 2). Different MDM2 inhibitors are currently under investigation in clinical trials. As for other targeted anti-cancer therapy approaches, relatively rapid resistance acquisition may limit the clinical efficacy of MDM2 inhibitors. In particular, MDM2 inhibitors were shown to induce p53 mutations in experimental systems. In the present article, we summarize what is known about MDM2 inhibitors as anti-cancer drugs with a focus on the acquisition of resistance to these compounds.

PMID:
25109953
DOI:
10.1042/BST20140035
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center